News & analysis on the clinical development and manufacture of large molecule drugs
Catalent, David Schaffer
By Ben Hargreaves
- Last updated on
With Catalent entering the gene therapy space, through the acquisition of Paragon Bioservices, the contract development and manufacturing organization (CDMO) has moved to bolster the knowledge base of its advisory board. To do so, David Shaffer has been appointed to the biologics advisory board of the company.
Mike Riley, VP and general manager of Catalent Biologics, stated that Shaffer’s appointment will allow the company to consult him on the development of viral vectors and the manufacturing technologies the company had brought on board through the acquisition.
Shaffer works at the University of California, Berkeley, as a professor of chemical and biomolecular engineering, whilst also working as a director of the Berkeley Stem Cell Center.
In addition, Shaffer holds the position of co-founder and chief scientific advisor at 4D Moleculer Therapeutics, a gene therapy company that works with adeno-associated viral (AAV) vectors to target specific tissue types.